These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32759604)

  • 1. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.
    Wada N; Uojima H; Satoh T; Okina S; Iwasaki S; Shao X; Takiguchi H; Arase Y; Itokawa N; Atsukawa M; Miyazaki K; Hidaka H; Kako M; Kagawa T; Iwakiri K; Horie R; Suzuki T; Koizumi W
    Dig Dis; 2021; 39(3):234-242. PubMed ID: 32759604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between response to lusutrombopag and splenic volume.
    Uojima H; Arase Y; Itokawa N; Atsukawa M; Satoh T; Miyazaki K; Hidaka H; Sung JH; Kako M; Tsuruya K; Kagawa T; Iwakiri K; Horie R; Koizumi W
    World J Gastroenterol; 2018 Dec; 24(46):5271-5279. PubMed ID: 30581275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function.
    Takeuchi H; Furuichi Y; Yoshimasu Y; Kasai Y; Abe M; Sugimoto K; Itoi T
    J Nippon Med Sch; 2021 Jan; 87(6):325-333. PubMed ID: 32238734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.
    Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Tanaka T; Sunago K; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Abe M; Joko K; Michitaka K; Hiasa Y
    J Gastroenterol Hepatol; 2020 Feb; 35(2):299-304. PubMed ID: 31318996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction of direct-acting antiviral agents alters frequencies of anti-GPIIb/IIIa antibody-producing B cells in chronic hepatitis C patients with thrombocytopenia.
    Satoh T; Uojima H; Wada N; Takiguchi H; Kaneko M; Nakamura M; Gonda N; Homma M; Hidaka H; Kusano C; Horie R
    Platelets; 2023 Dec; 34(1):2161498. PubMed ID: 36597279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
    Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Shimizu T; Watakabe K; Enomoto N; Izumi N
    PLoS One; 2019; 14(2):e0211122. PubMed ID: 30768601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between baseline clinical characteristics and efficacy of lusutrombopag in thrombocytopenic patients with chronic liver disease:
    Tanaka K; Baba T; Yoshida M; Iguchi M; Sonoyama T; Fukuhara T; Kano T
    Curr Med Res Opin; 2022 Feb; 38(2):303-310. PubMed ID: 34904508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia.
    Tsuji Y; Kawaratani H; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Takaya H; Shimozato N; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
    Dig Dis; 2020; 38(4):329-334. PubMed ID: 31655803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
    Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
    Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Katsube T; Shimizu R; Fukuhara T; Kano T; Wajima T
    Clin Pharmacokinet; 2019 Nov; 58(11):1469-1482. PubMed ID: 31055790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
    Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1192-1200. PubMed ID: 30502505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
    Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    J Gastroenterol; 2019 Feb; 54(2):171-181. PubMed ID: 30105510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis.
    Kajihara M; Kato S; Okazaki Y; Kawakami Y; Ishii H; Ikeda Y; Kuwana M
    Hepatology; 2003 Jun; 37(6):1267-76. PubMed ID: 12774004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.
    Sato S; Miyake T; Kataoka M; Isoda K; Yazaki T; Tobita H; Ishimura N; Kinoshita Y
    Intern Med; 2017 Nov; 56(21):2887-2890. PubMed ID: 28943563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura.
    Kuwana M; Okazaki Y; Kaburaki J; Kawakami Y; Ikeda Y
    J Immunol; 2002 Apr; 168(7):3675-82. PubMed ID: 11907134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
    Peck-Radosavljevic M; Simon K; Iacobellis A; Hassanein T; Kayali Z; Tran A; Makara M; Ben Ari Z; Braun M; Mitrut P; Yang SS; Akdogan M; Pirisi M; Duggal A; Ochiai T; Motomiya T; Kano T; Nagata T; Afdhal N
    Hepatology; 2019 Oct; 70(4):1336-1348. PubMed ID: 30762895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
    Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
    J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure.
    Shirley M; McCafferty EH; Blair HA
    Drugs; 2019 Oct; 79(15):1689-1695. PubMed ID: 31529283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell-activating factor is involved in thrombocytopenia in patients with liver cirrhosis.
    Satoh T; Takiguchi H; Uojima H; Kubo M; Tanaka C; Yokoyama F; Wada N; Miyazaki K; Hidaka H; Kusano C; Kuwana M; Horie R
    Ann Hematol; 2022 Nov; 101(11):2433-2444. PubMed ID: 36098792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus.
    Kuwana M; Kaburaki J; Okazaki Y; Miyazaki H; Ikeda Y
    Rheumatology (Oxford); 2006 Jul; 45(7):851-4. PubMed ID: 16418192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.